COO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
COO is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 to deploy, given the current mixed-to-bearish analyst backdrop, weak sentiment from recent downgrades, and only neutral technical momentum. The stock is near a key pivot with no clear breakout, and there is no strong proprietary buy signal today. I would hold off on buying right now rather than force an entry.
The price is 60.75, slightly below the pivot at 61.41 and close to support at 59.98. MACD histogram is positive at 0.488 but contracting, which suggests momentum is fading rather than strengthening. RSI_6 at 44.27 is neutral and does not show oversold strength. Moving averages are converging, indicating a lack of clear trend direction. Overall, the chart is range-bound to mildly weak, with no confirmed bullish setup.
No news in the recent week means no fresh event-driven catalyst is currently driving the stock. The only positives are that analysts like Needham and Barclays recently highlighted improving end markets, operating efficiencies, and margin expansion earlier in the year, which suggests the business still has some underlying operational strength. Options flow also leans mildly bullish.
Recent analyst actions turned more cautious, with Citi cutting its target to 69 and Goldman Sachs lowering to 61 while keeping a Sell rating. Goldman explicitly cited one of the weakest periods in MedTech in 15-20 years, pressured by weaker growth, reimbursement issues, competition, and valuation pressure. There is no recent news catalyst, no insider buying trend, and no congress trading data. Hedge fund and insider activity are both neutral.
No usable latest-quarter financial snapshot was provided due to a data error, so I cannot assess the most recent quarter directly. Based on the analyst commentary, the company previously showed improving sequential growth in Vision and Surgical and operating efficiency gains, but the current forward view has weakened. Since the latest quarter season is not available in the dataset, I cannot confirm current-quarter revenue or earnings growth.
Analyst sentiment has deteriorated recently. Citi reduced its target from 80 to 69 and maintained Neutral, while Goldman Sachs cut its target to 61 and kept Sell. Earlier in March, Needham and Barclays were constructive, raising targets and keeping Buy/Overweight, but the more recent revisions are clearly more negative. Wall Street is now split, but the near-term pros view is weaker than the cons view, with bearish concerns around growth, competition, and valuation dominating.
